Table 2 Cardiovascular and respiratory parameters at inclusion

Norepinephrine administration

28 (85%)

17 (94%)

11 (73%)

0.15

Norepinephrine dose (μg.kg^-1.min^-1)

0.98 (0.41–1.50)

0.68 (0.35–1.04)

1.32 (0.71–1.97)

0.12

Dobutamine administration

7 (21%)

4 (22%)

3 (20%)

1

Dobutamine dose (μg.kg^-1.min^-1)

10.0 (7.5–14.8)

11.4 (8.8–13.8)

10.0 (5.2–14.9)

0.86

Heart rate (min^-1)

100 (93–115)

102 (92–117)

100 (93–112)

0.69

MAP (mm Hg)

69 (64–72)

67 (62–71)

70 (68–72)

0.14

PPV (%)^a

7 (5–10)

7 (5–8)

7 (5–11)

0.92

CVP (mm Hg)

7 (5–11)

7 (5–10)

7 (4–11)

0.93

CI_TPTD (L.min^-1.m^-2)

2.75 (2.06–3.50)

2.94 (2.26–3.50)

2.70 (2.04–3.04)

0.48

GEDVI (ml.m^-2)

701 (587–854)

697 (586–866)

701 (614–773)

0.89

ELWI (ml.kg^-1 PBW)

14.6 (11.8–20.4)

15.8 (12.6–20.9)

13.7 (10.1–18.3)

0.23

Global ejection fraction (%)

16 (13–18)

16 (14–20)

16 (13–17)

0.66

Respiratory rate (min^-1)

30 (28–35)

30 (28–35)

30 (28–35)

0.84

Heart rate/respiratory rate ≤3.6

20 (61%)

10 (56%)

10 (67%)

0.72

Tidal volume (ml.kg^-1 PBW)

6.0 (5.9–6.1)

6.0 (6.0–6.1)

6.0 (5.9–6.0)

0.31

PEEP (cm H₂O)

8 (5–10)

8 (6–10)

8 (6–10)

0.67

PEEPt,rs (cm H₂O)

9 (8–11)

9 (8–11)

10 (8–12)

0.83

Pplat,rs (cm H₂O)

22 (20–27)

22 (20–28)

22 (18–26)

0.54

Driving pressure (cm H₂O)

12 (10–15)

13 (10–18)

11 (9–14)

0.23

Cst,rs (mL.cm H₂O^-1)

30 (23–39)

28 (21–38)

31 (25–43)

0.26

pH

7.33 (7.27–7.38)

7.31 (7.27–7.36)

7.38 (7.28–7.42)

0.20

PaO₂/FiO₂ (Torr)

158 (120–208)

155 (120–167)

207 (109–241)

0.17

PaCO₂ (Torr)

41 (38–51)

46 (41–52)

38 (36–44)

0.06

Arterial lactate (mmol.L^-1)

2.5 (1.9–6.4)

2.5 (1.9–6.3)

2.5 (1.8–5.8)

0.94